Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-06-25

Clinical Trial Results: Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluating evolocumab in high cardiovascular risk patients without prior myocardial infarction or stroke.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Evolocumab (evolocumab)

Snippet

Sponsor: Amgen | Conditions: Coronary Heart Disease (CHD) | Phase 3 | Status: COMPLETED | Results posted: 2026-06-25